Kerala govt forms committee to submit report on pediatric cough syrups

Thiruvananthapuram:  Kerala government constituted a committee to submit a report on the management of pediatric cough syrups following the death of at least 14 children after consumption of Coldrif syrup in Madhya Pradesh’s Chhindwara, Kerala Health Minister Veena George said on Tuesday.

Kerala Health Department has also asked the Drugs Controller to issue a notice to pharmacies not to sell pediatric drugs to children without a doctor’s prescription.

Veena George said that the State Drugs Controller has imposed a ban on the particular cough syrup, and the Kerala Medical Services Corporation (KMSCL) does not supply the syrup to government hospitals.

Speaking to ANI, Veena George said, “It’s unfortunate that 16 children died by consuming this cough syrup Coldrif. The Government of India has issued an advisory on the consumption of cough syrup. In Kerala, the Drugs Controller has issued a notification banning the particular cough syrup Coldrif in all the pharmacies across the state.”

“We don’t have this in our essential drugs list. This is not being supplied by the KMSCL, which is our corporation that supplies medicine to government hospitals. But, we are ensuring that the sale is not happening in private hospitals and pharmacies,” the Kerala Minister added.

She said that the committee on pediatric cough syrups will submit its report to the Kerala Government.

“We have already done this in the case of antibiotics and have strict enforcement in the State. We have established a committee that will submit a report to the government. The committee is particularly focused on the management of pediatric cough, because irrelevant combinations should not be in the syrups. We have decided to issue a guideline regarding the management of pediatric cough, which is very essential,” she said.

Furthermore, she alleged that doctors were prescribing cough syrups to children under the age of 2 years, which is not advisable.

Veena George said, “We do have a protocol on the consumption of cough syrup. It is not advisable to give cough syrups to children under 2 years old, but this case shows that doctors are prescribing cough syrups to children under 2 years old, which is unscientific and unacceptable. Kerala Health Department has asked the Drugs Controller to issue a notice to pharmacies not to give pediatric drugs to children without a prescription.”

Related Posts

WHO launches new primary health care course to strengthen health systems globally

Health is a human right – yet not everyone can access the health services they need, when and where they need them, without financial hardship. Primary health care (PHC) provides…

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

WHO launches new primary health care course to strengthen health systems globally

WHO launches new primary health care course to strengthen health systems globally

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert